Nyxoah S.A.

NYXH | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.41

-$0.07 (-4.73%)

Sep 22, 2026, 2:46 PM ET · Market open

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key Executives

Name	Position
Olivier Taelman	Chief Executive Officer & Executive Director
John Landry	Chief Financial Officer
An Moonen	General Counsel
Bruno Onkelinx	Chief Technical Officer
Geeta Kaveti	Chief Compliance Officer
Jeyakumar Subbaroyan	Chief Science Officer
Loic Moreau	President of International
Maggie McGowan	Chief HR Officer
Maurits S. Boon	Chief Medical Officer
Pearson Dennis	Investor Relations Associate
Robert Taub	Co-Founder & Chairman

Latest SEC Filings

Date	Type	Title
Aug 14, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Aug 05, 2026	6-K	Filing
Jul 09, 2026	6-K	Filing
Jul 01, 2026	SC 13G/A	[Amend] Statement of acquisition of beneficial own...
Jun 23, 2026	6-K	Filing
Jun 22, 2026	SC 13G	Statement of acquisition of beneficial ownership b...
Jun 11, 2026	6-K	Filing
Jun 11, 2026	SC 13D/A	[Amend] Filing
Jun 08, 2026	6-K	Filing
Jun 08, 2026	424B5	Filing

View All SEC Filings ➞

Nyxoah S.A.

Country	Belgium
IPO Date	Apr 27, 2021
Industry	Medical - Specialties
Sector	Healthcare
Employees	154
CEO	Olivier Taelman

Contact Details

Rue Edouard Belin 12 Mont-Saint-Guibert, Washington 1435 Belgium

https://www.nyxoah.com

32 1 022 23 55

Stock Details

Ticker Symbol	NYXH
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001857190
CUSIP Number	n/a
ISIN Number	BE0974358906
SIC Code	3841